Sivakami Mylvaganam, Rebecca Earnshaw, Gregory Heymann, Suneil K. Kalia and Lorraine V. Kalia* Pages 1038 - 1068 ( 31 )
Neurodegenerative diseases are characterized by the increasing dysfunction and death of neurons, resulting in progressive impairment of a person’s mobility and/or cognition. Protein misfolding and aggregation are commonly hypothesized to cause neurotoxicity and, eventually, neuronal degeneration that are associated with these diseases. Emerging experimental evidence, as well as recent findings from human studies, reveal that the C-terminus of Hsp70 Interacting Protein (CHIP), or STIP1 Homology and U-box containing Protein 1 (STUB1), is a quality control protein involved in neurodegeneration. Here, we review evidence that CHIP interacts with and plays a role in regulating proteins implicated in the pathogenesis of Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and polyglutamine diseases, including Huntington’s disease and spinocerebellar ataxias. We also review clinical findings identifying mutations in STUB1 as a cause of both autosomal recessive and autosomal dominant forms of cerebellar ataxia. We propose that CHIP modulation may have therapeutic potential for the treatment of multiple neurodegenerative diseases.
Alzheimer's disease, amyotrophic lateral sclerosis, cerebellar ataxia, huntington disease, neurodegenerative diseases, parkinson's disease, polyglutamine diseases, STUB1, STUB1-associated disease.
Department of Medicine, University of Toronto, Toronto, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Department of Medicine, University of Toronto, Toronto